76.8 F
San Diego
Wednesday, Jul 17, 2024
-Advertisement-

Investors Put $40M on TargeGen

TargeGen Inc., a San Diego company developing drugs to treat macular degeneration and other diseases, announced July 12 that it closed $40 million in funding.

New investors contributing to the Series D round were Innovis Investments, VantagePoint Venture Partners and CTI Life Sciences Fund. Existing investors participating in the financing included Forward Ventures, Enterprise Partners, Chicago Growth Partners/William Blair Capital Partners, CDP Capital, BB Biotech, Hambrecht & Quist Capital Management and Pappas Ventures.

TargeGen also announced July 12 that Peter Bissinger of Innovis Investments has joined its board.

, Brad Graves

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-